Clinical Trial Update: Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating paclitaxel with or without bevacizumab in locally recurrent or metastatic breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Eastern Cooperative Oncology Group | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED